Diabetic kidney disease Market: Epidemiology, Therapies, Companies, DelveInsight | DAIICHI SANKYO, PROKIDNEY, ASTRAZENECA, PALATIN, CHINOOK THERAPEUTICS, NOVARTIS, MINERALYS THERAPEUTICS, BOEHRINGER INGELHEIM, INVERSAGO PHARMA

Diabetic kidney disease therapies, such as MINNEBRO (esaxerenone/CS-3150), REACT (Renal Autologous Cell Therapy), JARDIANCE (empagliflozin), KERENDIA (Finerenone), and others, are expected to boost the Diabetic kidney disease Market in the upcoming years.

DelveInsight has launched a new report on "Diabetic kidney disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Diabetic kidney disease, historical and forecasted epidemiology as well as the Diabetic kidney disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Diabetic kidney disease market report @ https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Diabetic kidney disease Market Report:

In 2023, the United States represented the largest market for Diabetic Kidney Disease (DKD) among the 7MM (US, EU4, UK, and Japan), with an estimated market size of around USD 6.5 billion. DKD affects approximately 20-50% of people with diabetes and is the leading cause of end-stage kidney disease (ESKD) in many regions.
According to DelveInsight's projections, key diabetic kidney disease treatments expected to make a significant impact during the forecast period include Esaxerenone (CS-3150), REACT (cell therapy), atrasentan, zibotentan combined with dapagliflozin, among others.
Current treatment strategies primarily focus on stringent blood sugar and blood pressure control, along with the use of renin-angiotensin-aldosterone system (RAAS) blockers to slow disease progression. For years, no treatments existed specifically for DKD beyond RAAS inhibitors. However, the 2019 CREDENCE trial demonstrated the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors, adding a new class of therapeutic options for DKD patients.
On January 28, 2025, the U.S. Food and Drug Administration (FDA) approved Ozempic® (semaglutide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), for reducing the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). This approval is based on the pivotal Phase 3b FLOW trial, which demonstrated a 24% relative risk reduction in kidney-related events compared to placebo.
Key companies developing therapies for DKD include Daiichi Sankyo, ProKidney, AstraZeneca, Palatin, Chinook Therapeutics, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, and Inversago Pharma. Approved SGLT2 inhibitors like INVOKANA and FARXIGA are available in the US, Europe, and Japan, and JARDIANCE was approved in 2023 in the US and EU for chronic kidney disease (CKD), including patients without type 2 diabetes.
Among emerging therapies, mineralocorticoid receptor antagonists (MRAs) show significant promise. Bayer's KERENDIA, approved in the US in 2021 and in Europe and Japan in 2022, is a leading MRA for treating CKD linked to type 2 diabetes.
Currently, generics and off-label drugs dominate the DKD market due to their affordability and availability, posing challenges for new therapies to gain market share. Nonetheless, several investigational therapies are underway, including Daiichi Sankyo's esaxerenone, ProKidney's REACT, Inversago Pharma's INV-202, and AstraZeneca's zibotentan plus dapagliflozin combination.
In May 2023, Reata Pharmaceuticals discontinued its bardoxolone methyl trials (FALCON and EAGLE) based on recommendations from the Data Monitoring Committee, despite no safety concerns being found.
Esaxerenone is expected to gain an early foothold in the market due to its anticipated early launch, offering Daiichi Sankyo a competitive advantage. Meanwhile, ProKidney's REACT, a unique autologous cell-based therapy, is being developed to help preserve kidney function in high-risk diabetic patients.
Greater insight into DKD's underlying molecular pathways is essential for the advancement of novel therapies. Since DKD often progresses unnoticed in its early stages, predictive diagnostic tools could support timely clinical decisions, improving treatment outcomes and optimizing care strategies.
In 2023, the prevalence of diabetic kidney disease (DKD) across the 7MM was estimated at around 82.9 million cases, with numbers anticipated to rise over the forecast period. Of these, approximately 33.2 million were total diagnosed cases, which are also expected to grow by 2034.
Promising Diabetic kidney disease therapies include MINNEBRO (esaxerenone/CS-3150), REACT (Renal Autologous Cell Therapy), JARDIANCE (empagliflozin), KERENDIA (Finerenone), and others.

Diabetic kidney disease Overview

Diabetic kidney disease (DKD), also referred to as diabetic nephropathy, is a clinical condition marked by persistent albuminuria and a gradual decline in kidney function, reflecting a characteristic pattern of glomerular damage. DKD commonly occurs alongside high blood pressure and is linked to elevated risks of cardiovascular complications and mortality. While the condition has multiple contributing factors, chronic high blood sugar (hyperglycemia) is considered the primary driver. In its early stages, DKD may not present noticeable symptoms. As kidney function worsens, the accumulation of waste products in the body can lead to nausea, vomiting, reduced appetite, hiccups, and fluid retention, resulting in weight gain. If not properly managed, it can progress to heart failure and pulmonary edema (fluid in the lungs).

Diabetic kidney disease Market Outlook

Diabetic Kidney Disease (DKD), a form of chronic kidney disease (CKD) associated with diabetes, is the leading cause of end-stage renal disease. The progression of DKD is often linked to poor blood sugar control, and managing glucose levels while slowing the advancement of CKD has been a key goal in treating DKD patients. However, many glucose-lowering drugs (GLDs) present challenges, as they may be contraindicated or require careful dose adjustments for those with DKD. Managing blood sugar in patients with CKD is even more complex, as it necessitates a clear understanding of which medications are safe and how kidney disease influences drug metabolism. Early treatment options focused on ACE inhibitors (ACEi) and angiotensin II receptor blockers (ARBs). The introduction of SGLT2 inhibitors has brought about a significant shift in treatment approaches, showing promise in protecting kidney function for both diabetic and non-diabetic individuals with early kidney disease and detectable albumin in their urine. FDA-approved SGLT2 inhibitors for DKD include INVOKANA (canagliflozin), FARXIGA (dapagliflozin), and JARDIANCE (empagliflozin). Additionally, nonsteroidal mineralocorticoid receptor antagonists (MRA) and GLP-1 receptor agonists (GLP-1 RAs) are frequently used to treat DKD. KERENDIA (finerenone) has received FDA approval for individuals with kidney disease related to type 2 diabetes. The use of GLP-1 RAs is particularly recommended for those with kidney disease and heart conditions, such as heart attacks or coronary artery procedures like stents or bypass surgery.

The treatment landscape for DKD is evolving, with a multifaceted approach that includes managing diabetes, controlling blood pressure, and slowing kidney damage. The market is dynamic, and emerging therapies like REACT, zibotentan combined with dapagliflozin, esaxerenone, and others are expected to further enhance the treatment options for DKD. The launch of these key therapies, coupled with the increasing prevalence of DKD, is expected to drive growth in the DKD treatment market over the coming years.

Discover how the Diabetic kidney disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Kidney Disease Marketed Drugs
JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly
KERENDIA (Finerenone): Bayer

Diabetic kidney disease Emerging Drugs
MINNEBRO (esaxerenone/CS-3150): Daiichi Sankyo
REACT (Renal Autologous Cell Therapy): ProKidney

Scope of the Diabetic kidney disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Diabetic kidney disease Companies: DAIICHI SANKYO, PROKIDNEY, ASTRAZENECA, PALATIN, CHINOOK THERAPEUTICS, NOVARTIS, MINERALYS THERAPEUTICS, BOEHRINGER INGELHEIM, INVERSAGO PHARMA, and others
Key Diabetic kidney disease Therapies: MINNEBRO (esaxerenone/CS-3150), REACT (Renal Autologous Cell Therapy), JARDIANCE (empagliflozin), KERENDIA (Finerenone), and others
Diabetic kidney disease Therapeutic Assessment: Diabetic kidney disease current marketed and Diabetic kidney disease emerging therapies
Diabetic kidney disease Market Dynamics: Diabetic kidney disease market drivers and Diabetic kidney disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Diabetic kidney disease Unmet Needs, KOL's views, Analyst's views, Diabetic kidney disease Market Access and Reimbursement

To know what's more in our Diabetic kidney disease report, visit https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Diabetic kidney disease Market Report:
Diabetic kidney disease market report covers a descriptive overview and comprehensive insight of the Diabetic kidney disease Epidemiology and Diabetic kidney disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Diabetic kidney disease market report provides insights into the current and emerging therapies.
The Diabetic kidney disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Diabetic kidney disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diabetic kidney disease market.

Got queries? Click here to know more about the Diabetic kidney disease market Landscape https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Diabetic kidney disease Patient Share (%) Overview at a Glance
5. Diabetic kidney disease Market Overview at a Glance
6. Diabetic kidney disease Disease Background and Overview
7. Diabetic kidney disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic kidney disease
9. Diabetic kidney disease Current Treatment and Medical Practices
10. Unmet Needs
11. Diabetic kidney disease Emerging Therapies
12. Diabetic kidney disease Market Outlook
13. Country-Wise Diabetic kidney disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Diabetic kidney disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Diabetic kidney disease Market Outlook 2034 https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Diabetic kidney disease Pipeline Insights, DelveInsight

"Diabetic kidney disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Diabetic kidney disease market. A detailed picture of the Diabetic kidney disease pipeline landscape is provided, which includes the disease overview and Diabetic kidney disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.